CeQur SA raises USD 115 Million Series C5 Financing Round
13. April 2021 – CeQur SA a Swiss medical device company committed to simplifying the lives of people with diabetes by revolutionizing insulin-delivery solutions, announced the close of an oversubscribed $115 million equity financing.
The company will use the funds to advance commercial plans for CeQur Simplicity™, including market development activities, a phased commercial launch strategy that includes a limited market release in 2021, and the scale-up of high-volume manufacturing. CeQur Simplicity is both FDA cleared and CE-marked.
Credit Suisse Entrepreneur Capital Ltd and Endeavour Vision led the financing with significant participation from new investors, including Tandem Diabetes Care, Inc. (NASDAQ: TNDM), Ypsomed Group (SWX: YPSN), Federated Hermes Kaufmann Funds, Kingdon Capital, and GMS Capital, as well as existing investors, Schroder & Co. Bank SA, and VI Partners.
Walder Wyss AG advised CeQur SA in the financing. The team was led by Patrick W. Vogel (Partner, Corporate/M&A) and included André Kuhn (Managing Associate, Corporate/M&A), Camille Tistounet (Trainee Lawyer) and Leandro Schafer (Trainee Lawyer).